Catalyst Pharmaceuticals (CPRX) 10-Q2024 Q3 Quarterly report

Filed: 6 Nov 24, 4:08pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: accessible, accessing, adjacent, analytical, API, ASU, attempted, attract, automatic, automatically, backbone, billion, bring, competitor, compound, concomitantly, contested, correspondingly, cyber, deeper, demonstrate, denominated, Department, diagnostic, earliest, EC, embedded, enhanced, Equivalence, Family, filer, flexibility, Foundation, gather, gene, Germany, Hetero, hope, inclusive, indefinite, infrastructure, installment, Inventia, kg, Kingdom, Labour, lapse, Latin, leader, lifecycle, literature, Lupin, manner, MHRA, Ministry, Myasthenia, ODE, Pacific, panel, permitted, phishing, plc, pocket, prevail, prospectively, ransomware, reconciliation, registry, release, reset, retrospectively, revocation, run, ruzurgi®, satisfaction, scheduled, scientific, solution, sublicensee, SUMMIT, supplier, switched, tentative, Teva, thought, TSA, underinsured, unforeseen, unsuccessful, unwavering, weighing, Welfare

Removed: aa, adversely, allege, arise, built, Chief, closely, collection, cycle, defend, division, driven, Eleventh, emergency, employment, epileptic, evaluated, exchanged, execute, execution, flagship, governed, hired, hiring, incur, Initially, initiative, inside, insignificant, institution, integrate, lessen, limit, minimal, moved, neurological, nominal, onForm, output, pandemic, partial, pipeline, pivotal, prepare, prescribed, putting, regularly, removed, retaining, robust, roughly, salary, South, structure, targeted, telemarketing, transactional, trued, underASC, worked, worldwide

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Associated CPRX transcripts

CPRX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Certification Required by 18 U.S.C. Section 1350

(as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002)

I, Richard J. Daly as Principal Executive Officer of Catalyst Pharmaceuticals, Inc. (the Company), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge:

the accompanying Quarterly Report on Form 10-Q of the Company for the quarterly period ended September 30, 2024 (the Report), filed with the U.S. Securities and Exchange Commission, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: November 6, 2024			/s/ Richard J. Daly
			Richard J. Daly
			President and Chief Executive Officer
			(Principal Executive Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.